title: The present state of antineoplaston research (1).
abstract: Antineoplastons work as molecular switches, which regulate expression of genes p53 and p21 through demethylation of promoter sequences and acetylation of histones. They also inhibit the uptake of growth-critical amino acids, such as 1-glutamine and 1-leucine in neoplastic cells. Phase II trials indicate efficacy of antineoplastons in low-grade glioma, brain stem glioma, high-grade glioma, adenocarcinoma of the colon, and hepatocellular carcinoma. The best results were observed in children with low-grade glioma, where 74% of patients obtained objective response, and in patients with adenocarcinoma of the colon with liver metastases whose survival rate of more than 5 years is 91% versus 39% in controls on chemotherapy. Gene array studies will explain antineoplaston-induced changes in gene expression.
authors.affiliation: Burzynski Research Institute, Houston, TX 77055, USA. info@burzynskiclinic.com
authors.forename: Stanislaw R
authors.initials: SR
authors.lastname: Burzynski
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D044482:Benzeneacetamides / Q000494:pharmacology / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D002648:Child; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy*; D000529:Complementary Therapies; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000187:drug effects*; D016158:Genes, p53; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D010881:Piperidones / Q000494:pharmacology / Q000627:therapeutic use*; D016019:Survival Analysis
chemical_list: D044482:Benzeneacetamides; D010881:Piperidones